4 research outputs found
Prevalence of Post COVID-19 Condition among Healthcare Workers: Self-Reported Online Survey in Four African Countries, December 2021–January 2022
The impact of Post COVID-19 Condition (PCC) is ongoing despite the declaration that the 2019 COVID-19 pandemic has ended. In this study, we explore the prevalence of PCC among healthcare workers (HCWs) in four African Countries and its influence on their professional performance. This study was conducted as an online cross-sectional survey of healthcare workers from four African countries (Cameroon, Egypt, Nigeria, and Somalia) between the 20th of December 2021 to 12th of January 2022. We determined the prevalence of PCC based on the WHO case definition and assessed variables associated with a higher prevalence of PCC in these countries using univariable and multivariable logistic regression analyses. A total of 706 HCWs from four African countries were included in this survey. Most of the HCWs were aged between 18–34 years (75.8%, n = 535). Our findings showed that 19.5% (n = 138) of the HCWs had tested positive for SARS-CoV-2. However, 8.4% (n = 59) were symptomatic for COVID-19 but tested negative or were never tested. Two-thirds of the HCWs (66.4%, n = 469) have received a COVID-19 vaccine and 80.6% (n = 378) of those vaccinated had been fully vaccinated. The self-reported awareness rate of PCC among the HCWs was 16.1% (n = 114/706) whereas the awareness rate of PCC among COVID-19-positive HCWs was 55.3% (n = 109/197). The prevalence of PCC among HCWs was 58.8% (n = 116). These changes include the self-reported symptoms of PCC which included headache (58.4%, n = 115), fatigue (58.8%, n = 116), and muscle pain (39.6%, n = 78). Similarly, 30% (n = 59) and 20.8% (n = 41) of the HCWs reported the loss of smell and loss of taste long after their COVID-19 infection, respectively. Some HCWs (42%, n = 83) believed that their work performance has been affected by their ongoing symptoms of PCC. There was no significant difference in the prevalence of PCC among the vaccinated and unvaccinated HCWs (p > 0.05). Of the socio-demographic variables, age (older HCWs between 45–54 years; OR:1.7; 95% CI: 1.06, 10.59; p = 0.001) and location (Egypt; OR:14.57; 95% CI: 2.62, 26.76; p = 0.001) were more likely to have experienced PCC than other age groups and countries respectively. The study revealed a low prevalence of PCC among the surveyed HCWs. In addition, it observed the need for adequate medical and psychological support to HCWs with PCC and improved mass advocacy campaigns on PCC
Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa
Local, national, and international health agencies have advocated multi-pronged public health strategies to limit infections and prevent deaths. The availability of safe and effective vaccines is critical in the control of a pandemic. Several adverse events have been reported globally following reception of different vaccines, with limited or no data from Africa. This cross-sectional epidemiological study investigated adverse events following COVID-19 vaccination in Africans from April–June, 2021 using a structured online questionnaire. Out of 1200 participants recruited, a total of 80.8% (n = 969) respondents from 35 countries, including 22 African countries and 13 countries where Africans live in the diaspora, reported adverse events. Over half of the vaccinees were male (53.0%) and frontline healthcare workers (55.7%), respectively. A total of 15.6% (n = 151) reported previous exposure to SARS-CoV-2, while about one-fourth, 24.8% (n = 240), reported different underlying health conditions prior to vaccination. Fatal cases were 5.1% (n = 49), while other significant heterogenous events were reported in three categories: very common, common, and uncommon, with the latter including enlarged lymph nodes 2.4% (n = 23), menstrual disorder 0.5% (n = 5), and increased libido 0.2% (n = 2). The study provided useful data for concerned authorities and institutions to prepare plans that will address issues related to COVID-19 vaccines
Prevalence of post COVID-19 condition among healthcare workers : self-reported online survey in four African countries, December 2021-January 2022
DATA AVAILABILITY STATEMENT : The datasets used and/or analyzed during the current study are
available from the corresponding author upon reasonable request.SUPPLEMENTARY MATERIALS : TABLE S1: COVID-19 vaccination status in the four African countries as of 6th June 2023 [30]. TABLE S2: Association between the nationality of HCWs and their COVID-19 positivity, vaccination rate, and awareness of PCC.The impact of Post COVID-19 Condition (PCC) is ongoing despite the declaration that
the 2019 COVID-19 pandemic has ended. In this study, we explore the prevalence of PCC among
healthcare workers (HCWs) in four African Countries and its influence on their professional performance.
This study was conducted as an online cross-sectional survey of healthcare workers from four
African countries (Cameroon, Egypt, Nigeria, and Somalia) between the 20th of December 2021 to
12th of January 2022. We determined the prevalence of PCC based on the WHO case definition and
assessed variables associated with a higher prevalence of PCC in these countries using univariable
and multivariable logistic regression analyses. A total of 706 HCWs from four African countries were included in this survey. Most of the HCWs were aged between 18–34 years (75.8%, n = 535). Our
findings showed that 19.5% (n = 138) of the HCWs had tested positive for SARS-CoV-2. However,
8.4% (n = 59) were symptomatic for COVID-19 but tested negative or were never tested. Two-thirds of
the HCWs (66.4%, n = 469) have received a COVID-19 vaccine and 80.6% (n = 378) of those vaccinated
had been fully vaccinated. The self-reported awareness rate of PCC among the HCWs was 16.1%
(n = 114/706) whereas the awareness rate of PCC among COVID-19-positive HCWs was 55.3%
(n = 109/197). The prevalence of PCC among HCWs was 58.8% (n = 116). These changes include the
self-reported symptoms of PCC which included headache (58.4%, n = 115), fatigue (58.8%, n = 116),
and muscle pain (39.6%, n = 78). Similarly, 30% (n = 59) and 20.8% (n = 41) of the HCWs reported the
loss of smell and loss of taste long after their COVID-19 infection, respectively. Some HCWs (42%,
n = 83) believed that their work performance has been affected by their ongoing symptoms of PCC.
There was no significant difference in the prevalence of PCC among the vaccinated and unvaccinated
HCWs (p > 0.05). Of the socio-demographic variables, age (older HCWs between 45–54 years; OR:1.7;
95% CI: 1.06, 10.59; p = 0.001) and location (Egypt; OR:14.57; 95% CI: 2.62, 26.76; p = 0.001) were more
likely to have experienced PCC than other age groups and countries respectively. The study revealed
a low prevalence of PCC among the surveyed HCWs. In addition, it observed the need for adequate
medical and psychological support to HCWs with PCC and improved mass advocacy campaigns
on PCC.https://www.mdpi.com/journal/covidam2024Veterinary Tropical DiseasesSDG-03:Good heatlh and well-bein
Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa
Local, national, and international health agencies have advocated multi-pronged public health strategies to limit infections and prevent deaths. The availability of safe and effective vaccines is critical in the control of a pandemic. Several adverse events have been reported globally following reception of different vaccines, with limited or no data from Africa. This cross-sectional epidemiological study investigated adverse events following COVID-19 vaccination in Africans from April–June, 2021 using a structured online questionnaire. Out of 1200 participants recruited, a total of 80.8% (n = 969) respondents from 35 countries, including 22 African countries and 13 countries where Africans live in the diaspora, reported adverse events. Over half of the vaccinees were male (53.0%) and frontline healthcare workers (55.7%), respectively. A total of 15.6% (n = 151) reported previous exposure to SARS-CoV-2, while about one-fourth, 24.8% (n = 240), reported different underlying health conditions prior to vaccination. Fatal cases were 5.1% (n = 49), while other significant heterogenous events were reported in three categories: very common, common, and uncommon, with the latter including enlarged lymph nodes 2.4% (n = 23), menstrual disorder 0.5% (n = 5), and increased libido 0.2% (n = 2). The study provided useful data for concerned authorities and institutions to prepare plans that will address issues related to COVID-19 vaccines